Frankfurt
22.04.25
08:14 Uhr
0,061 Euro
+0,001
+2,34 %
+2,34 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,092 | 0,094 | 13:37 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 143 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF Listing: Euronext Growth Paris
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing:... ► Artikel lesen | |
| 01.04. | Mauna Kea Technologies Announces Entrance Into Exclusive Negotiations for a Licensing Agreement for Cellvizio in an Important Therapeutic Area With a Major Industry Player | 270 | Business Wire | The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify... ► Artikel lesen | |
| 31.03. | Mauna Kea Technologies Announces the Opening of a Safeguard Proceeding to Restructure Its Financial Liabilities | 486 | Business Wire | The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The procedure will also provide a protective framework favorable... ► Artikel lesen | |
| 06.03. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 237 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.03. | Mauna Kea Technologies: Cellvizio Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis | 244 | Business Wire | ESGE, Europe's leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step towards broader commercial adoption
Regulatory... ► Artikel lesen | |
| 06.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 245 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 27.01. | Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio for Precision Surgery in Head and Neck Cancers | 337 | Business Wire | Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx, oropharynx and hypopharynx Cellvizio helped identify... ► Artikel lesen | |
| 21.01. | Mauna Kea Technologies: Half-Year Liquidity Contract Statement for H2 2024 With the Brokerage Firm Gilbert Dupont | 633 | Business Wire | Regulatory News:
Under the liquidity contract between the company MAUNA KEA TECHNOLOGIES (Paris:ALMKT) and the brokerage firm Gilbert Dupont, the following resources appeared on the liquidity account... ► Artikel lesen | |
| 20.01. | Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex | 345 | Business Wire | 13th U.S. AI patent awarded to Mauna Kea Expanded patent portfolio boosts platform value, supports strategic partnerships
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT)... ► Artikel lesen | |
| 15.01. | Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update | 413 | Business Wire | Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks RM Global and Bucephale Finance mandated to... ► Artikel lesen | |
| 14.01. | Mauna Kea Technologies Announces Its 2025 Financial Calendar | 260 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®,the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces... ► Artikel lesen | |
| 09.01. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 421 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.12.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 381 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 26.11.24 | Mauna Kea Technologies: Raising Pancreatic Cancer Awareness Through Patient Voices | 182 | Business Wire | With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic Cancer
Regulatory News:
This Pancreatic Cancer Awareness Month... ► Artikel lesen | |
| 20.11.24 | Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador | 127 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is pleased... ► Artikel lesen | |
| 13.11.24 | Mauna Kea Technologies Provides an Update on Its Recent Developments | 357 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides... ► Artikel lesen | |
| 06.11.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 332 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website:... ► Artikel lesen | |
| 17.10.24 | Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance | 430 | Business Wire | Major New Study Presented at the World's Largest Gastroenterology Congress Validation of Mauna Kea's Growth Strategy with CellTolerance® in a $6 Billion a Year Market Opportunity
Regulatory... ► Artikel lesen | |
| 15.10.24 | Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales | 422 | Business Wire | Confirmation of lower breakeven point trajectory with 9% Reduction in Operational Expenses Q3 2024 Sales Growth of +24%1 Driven by New System Sales in the U.S. and Europe Official Launch of... ► Artikel lesen | |
| 04.10.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 492 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,133 | +5,56 % | Sernova Biotherapeutics Inc: Sernova closes $4-million term loan from Navigate | ||
| FAMICORD | 4,000 | -2,91 % | EQS-Adhoc: FamiCord AG: FamiCord übertrifft Jahresprognose 2024 auf Basis vorläufiger Zahlen ergebnisseitig wesentlich | EQS-Ad-hoc: FamiCord AG / Schlagwort(e): Jahresergebnis/Prognose
FamiCord AG übertrifft Jahresprognose 2024 auf Basis vorläufiger Zahlen ergebnisseitig wesentlich
10.04.2025 / 17:35... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,840 | 0,00 % | Geratherm Medical Aktie: Ruhige Zeiten angekündigt? | Das Medizintechnikunternehmen passt Produktionskapazitäten für klinische Thermometer bei fortgesetzter Marktschwäche an, während die Aktie trotz Volatilität zuletzt zulegte. Die Geratherm Medical AG... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,647 | 0,00 % | Plus Therapeutics: ReSPECT-LM Data Shows Potential Utility Of REYOBIQ | WASHINGTON (dpa-AFX) - Plus Therapeutics (PSTV) reported the online availability of new data on its lead compound REYOBIQ. The additional data from the Phase 1 ReSPECT-LM dose escalation trial... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,540 | -1,46 % | Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer | CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM)... ► Artikel lesen | |
| MEDICLIN | 2,900 | 0,00 % | EQS-News: MEDICLIN AG: MEDICLIN beendet erfolgreiches Geschäftsjahr 2024 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Jahresbericht/Sonstiges
MEDICLIN beendet erfolgreiches Geschäftsjahr 2024
28.03.2025 / 10:24 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,065 | -100,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-Q, Quarterly Report | ||
| VERU | 0,460 | -2,38 % | Veru Aktie: Bedeutet das eine Neuausrichtung? | Die Veru-Aktie verliert weiter an Wert, doch Analysten bleiben optimistisch aufgrund vielversprechender Medikamentenentwicklungen. Wird der Tiefpunkt bald erreicht? Die Veru-Aktie setzt ihre Abwärtsspirale... ► Artikel lesen | |
| LIFEWARD | 1,420 | 0,00 % | LFWD Stock Falls Despite Launch of Next-Generation Mobility ReWalk 7 | ||
| LIGHT AI | 0,347 | +11,22 % | Light AI Inc: Light AI adds expands wellness app | ||
| EKSO BIONICS | 0,392 | +9,50 % | Ekso Bionics Holdings Aktie: Beeindruckende Innovationskraft | Der Exoskelett-Hersteller verzeichnet im letzten Quartal 2024 Umsatzsteigerungen und Margenwachstum, kämpft jedoch mit Jahresrückgang bei hoher Aktienvolatilität. Ekso Bionics meldete für das vierte... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 53,43 | 0,00 % | Piper Sandler maintains $100 target on Procept BioRobotics stock | ||
| FRESENIUS | 39,190 | +0,46 % | Fresenius SE Aktie: Leichte Erholung im Fokus | Fresenius notiert nahe dem Jahreshoch mit soliden technischen und fundamentalen Signalen. Analysten sehen weiteres Kurspotenzial trotz hoher Verschuldung. Die Fresenius-Aktie zeigt sich am Donnerstag... ► Artikel lesen |
Das Unternehmen MAUNA KEA TECHNOLOGIES kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,34 % bei einem Aktienkurs von 0,061 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.
